SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of HemaCare Corporation to Charles River Laboratories International, Inc. is Fair to Shareholders
NEW YORK, NY / ACCESSWIRE / December 16, 2019 / The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased HemaCare Corporation ("HemaCare" or the "Company") (OTCMKTS:HEMA) stock prior to December 16, 2019.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of HemaCare to Charles River Laboratories International, Inc. ("Charles River") (NYSE: CRL). Under the terms of the agreement, proposed purchase price equates to $25.40 per HemaCare share. To learn more about the action and your rights, go to:
https://www.zlk.com/mna/hemacare-corporation
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.
The HemaCare merger investigation concerns whether the Board of HemaCare breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether Charles River is underpaying for HemaCare shares, thus unlawfully harming HemaCare shareholders.
Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
ReleaseID: 570370